The Joint swings to $117,000 consolidated net loss in Q3 2026 from year-earlier profit
JYNT•The Joint reported a $117,000 consolidated net loss in Q3 2026, while net income from continuing operations rose to $1.5 million and revenue increased to $13.6 million. The board authorized an additional $5 million in stock repurchases after $3.8 million of buybacks during the quarter.
1. Quarterly results and buybacks
The Joint swung to a consolidated net loss of $117,000 in Q3 2026 from a year-earlier profit. Net income from continuing operations rose to $1.5 million year over year, and revenue increased to $13.6 million. After repurchasing $3.8 million of stock during the quarter, the board authorized an additional $5 million in buybacks. Underperforming clinic closures are expected to leave the 2026 year-end clinic count approximately 50 below the 2025 year-end total.
